We use cookies to improve this site and enable full functionality. You can change your cookie settings at any time using your browser. Our cookie policy.

Global insurtech funding trend slashed by over 50% amid COVID-19

Global insurtech funding trend slashed by over 50% amid COVID-19 | Insurance Business

Global insurtech funding trend slashed by over 50% amid COVID-19

The quarterly global insurtech funding trend has been slashed by more than 50%, a likely victim of the COVID-19 pandemic, according to a new report from Willis Towers Watson. However, despite the “clear impact” of the outbreak on insurtech investment worldwide, insurtechs raised a total of US$912 billion during the first quarter.

Deal count for Q1 was at 96, up 28% from Q4 2019, according to Willis Towers Watson’s Quarterly InsurTech Briefing. Year over year, deal count in Q1 was up 10%.  It was the highest number of investment rounds by transactional volume ever recorded by the Quarterly InsurTech Briefing.

However, overall funding was down by 54%, a drop driven largely by far fewer “mega-deals” – deals of US$100 million or more – taking place so far this year. In 2019, multiple unicorn-making rounds supported eight of the 10 insurtech firms valued at more than US$1 billion – giving five of them unicorn status in the process, according to Willis Towers Watson. Q1 2020, however, included no unicorn-making rounds and only one mega-round – the US$100 million Series D issue by PolicyGenius.

The US recorded 57% of deals, while the UK recorded 10%, according to Willis Towers Watson. Deal flow in Asia was down, but the Czech Republic posted its first ever public insurtech deal.

Seed and Series A financing fell 9% from the previous quarter at US$223 million, but early-stage deal count rose three percentage points to 51% of all deals. As a percentage of all funding, early-stage deal investment rose 12 percentage points.

Insurtechs focused on property and casualty insurance increased their share of total funding to 83%, the largest gap with life and health funding since Q3 of 2016. B2B-focused companies accounted for 55% of recorded deals in Q1, a 121% increase from Q4 2019, Willis Towers Watson reported. The value of strategic investments by reinsurers fell 8% from Q4 2019 and 43% from its peak in Q3 2019.

“This has been a particularly interesting quarter for global insurtech,” said Dr. Andrew Johnson, global head of insurtech at Willis Re. “It is clear that COVID-19 has had a material impact on later-stage investments, and reinsurers are holding back. Despite the very large percentage drop this quarter when compared with the last, we are still seeing a huge amount of activity in early-stage funding rounds, across a very large number of deals. The relative downturn of reinsurer participation in this round would explain why we have seen fewer mega-deals, affecting the overall amount raised significantly, which is not surprising as reinsurers increasingly participate in later stages. Again, COVID-19 is a likely culprit for less engagement from industry capital as reinsurers focus their attention on other, perhaps more pressing issues.”